Want to see AGL full AI Analyst Report?
AGL Stock Chart & Stats
$98.00
-$2.27(-2.26%)
At close: 4:00 PM EDT
$98.00
-$2.27(-2.26%)
Day’s Range― - ―
52-Week Range$7.48 - $133.04
Previous CloseN/A
Volume247.62K
Average Volume (3M)322.23K
Market Cap
$1.57B
Enterprise Value$1.62K
Total Cash (Recent Filing)$185.63M
Total Debt (Recent Filing)$33.45M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Oct 29, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.38
Shares Outstanding16,791,210
10 Day Avg. Volume342,073
30 Day Avg. Volume322,225
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.25
Price to Sales (P/S)0.05
P/FCF Ratio-2.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$116.22Price Target Upside18.59% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$5.80B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp improvement in medical margin and adjusted EBITDA, alongside raised 2026 guidance, indicates better execution and operating leverage. Sustaining this progress could strengthen the value-based care model and reduce dependence on external funding.
Clinical And Data CapabilitiesDemonstrated clinical savings and high quality scores support Agilon’s ability to manage senior-care costs under risk contracts. Broad pathway deployment and data from over 80% of payers can improve diagnosis, intervention timing, and contract economics.
Manageable Leverage And LiquidityLow reported leverage and substantial available liquidity provide a buffer while the company works through losses and medical-cost volatility. This financial flexibility supports continued investment in technology, care programs, and physician partnerships.
Bears Say
Persistent Losses And Cash BurnOngoing losses and negative operating and free cash flow show that the business has not yet become self-funding. Continued cash consumption could constrain investment capacity and make durable profitability dependent on further medical-margin improvement.
Medicare Advantage Membership DeclineThe membership contraction reduces the attributed population supporting recurring capitated revenue and limits scale benefits across physician partnerships. Although management cited disciplined contracting, rebuilding membership remains important for longer-term growth.
Medical Cost And Contracting UncertaintyElevated medical-cost trends can compress margins in risk-bearing contracts, particularly when claims visibility is limited. Unresolved 2027 pricing and contracting add uncertainty to future membership, reimbursement, and the sustainability of recent performance gains.
Agilon Health News
AGL FAQ
What was Agilon Health Inc’s price range in the past 12 months?
Agilon Health Inc lowest stock price was $7.48 and its highest was $133.04 in the past 12 months.
What is Agilon Health Inc’s market cap?
Agilon Health Inc’s market cap is $1.57B.
When is Agilon Health Inc’s upcoming earnings report date?
Agilon Health Inc’s upcoming earnings report date is Oct 29, 2026 which is in 69 days.
How were Agilon Health Inc’s earnings last quarter?
Agilon Health Inc released its earnings results on Aug 05, 2026. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.144 by $0.896.
Is Agilon Health Inc overvalued?
According to Wall Street analysts Agilon Health Inc’s price is currently Undervalued.
Does Agilon Health Inc pay dividends?
Agilon Health Inc pays a Quarterly dividend of $0.45 which represents an annual dividend yield of N/A. See more information on Agilon Health Inc dividends here
What is Agilon Health Inc’s EPS estimate?
Agilon Health Inc’s EPS estimate is -1.22.
How many shares outstanding does Agilon Health Inc have?
Agilon Health Inc has 16,791,210 shares outstanding.
What happened to Agilon Health Inc’s price movement after its last earnings report?
Agilon Health Inc reported an EPS of $1.04 in its last earnings report, beating expectations of $0.144. Following the earnings report the stock price went down -19.49%.
Which hedge fund is a major shareholder of Agilon Health Inc?
Currently, no hedge funds are holding shares in AGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilon Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$116.22 (18.59% Upside)
$116.22 (18.59% Upside)
Blogger Sentiment
Bullish
AGL Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.10%
Trailing 12-Months
Company Description
Agilon Health Inc
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
AGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially improved financial performance in Q2 (revenue growth, a large swing to positive medical margin, and a return to positive adjusted EBITDA), uplift from better-than-expected risk adjustment and stronger clinical program execution (CHF, Burden of Illness, ACO REACH). Management also highlighted enhanced data capabilities and ongoing AI/clinical pathway investments as durability drivers. Offsets and near-term risks include a year-over-year decline in MA membership driven by disciplined contracting, ongoing cost trend pressures (conservative reserving and ~7% cost trend assumptions for the back half), Part D exposure complexities, and uncertainty around 2027 contracting and membership. Overall, positives (financial turnaround, risk adjustment uplift, clinical program outcomes, and improved data visibility) outweigh the operational and timing headwinds, supporting constructive visibility into 2026 and a cautiously optimistic view into 2027.View all AGL earnings summariesAGL Stock 12 Month Forecast
Average Price Target
$116.22
▲(18.59% Upside)
Technical Analysis
Ownership Overview
5.63% Insiders
16.51% Mutual Funds
41.28% Other Institutional Investors
26.45% Public Companies and
Individual Investors